Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report 3 Undervalued Names Too Cheap to IgnoreWritten by Nathan Reiff. Date Posted: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, some fairly sizeable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below all represent potential value plays, featuring value metrics that are historically low and/or competitive relative to peers or the broader market. They also offer additional benefits, such as compelling dividends or promising new product developments. While pure value opportunities can be harder to find when many high-growth names have regained investor attention—and some apparent value plays hide deteriorating fundamentals—well-established and stable names can still be attractive prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Despite a more than 28% gain over the last year that pushed its market capitalization close to $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) trades at a price-to-earnings (P/E) ratio of about 16.45—well below the medical-industry average of roughly 27. Analysts expect earnings to rise nearly 10% in the coming year, and the stock carries an estimated 5% of additional upside in the near term. Helping drive Merck's momentum is its pembrolizumab cancer drug, Keytruda, which was approved for subcutaneous injection by the European Commission in late 2025 and generated about $8.4 billion in sales in Q4 2025, up roughly 7% year over year. Keytruda also shows promise for ovarian cancer treatments, potentially expanding its patient base. These trends should help Merck build revenue as it prepares for Keytruda's patent expiration in 2028. Merck's pipeline is broadening as well: the company recently announced phase 3 trial results for clesrovimab-cfor (Enflonsia), a potential RSV treatment for young children. At the same time, Merck has reorganized its human health division into two units to make it easier to grow its non-cancer-drug business ahead of Keytruda's loss of exclusivity. A Difficult External Situation Pressures Campbell's, but Strong Dividend and Value Remain Campbell's (NASDAQ: CPB) has seen its shares fall about 37% over the past year as tariffs and inflation squeezed the food-and-beverage company. In Q1 fiscal 2026 (ended Nov. 2, 2025), Campbell's reported modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share fell about 13%. Margin improvement has been slow to materialize despite cost-saving efforts. The near term is likely to remain challenging, with generally weak fiscal-year guidance. Still, improvements in the supply chain and strong brand loyalty—especially for premium offerings—should provide some protection. Evolving tariff dynamics could also ease cost pressures over time. Crucially for income-focused investors, Campbell's offers an attractive dividend yield of 5.9%, although the payout ratio is relatively high at over 80%. Its P/E ratio of about 13.5 is the lowest in roughly four years. Those elements may persuade some investors that the stock is worth considering despite Wall Street caution. A Recent US Foods Rally May Continue, and Bottom-Line Growth Remains in Place Foodservice distributor US Foods (NYSE: USFD) has seen the opposite trajectory of Campbell's—its shares are up roughly 33% over the past year. Even after the rally, the stock's valuation (P/E around 31.6) remains reasonable relative to some peers and the growth expected. On the fundamentals, US Foods reported improved profitability in the latest quarter and posted full-year adjusted EBITDA gains of 11% year over year. Better inventory management and cost-of-goods savings have helped the company regain momentum. With a $4 billion capital deployment plan, US Foods is positioned to sustain revenue growth and continue expanding adjusted EBITDA. Analysts rate USFD a Moderate Buy (11 Buys and 2 Holds), implying roughly 15% upside potential.
| 
